Indian Pharma Companies Strengthen in US

By admin • August 12th, 2010

Subscribe to Hexxcom's RSS feed to get the latest Updates. Thanks for visiting!

According to data from the IMS Health, Indian pharmaceutical companies have moved up the rankings in the US generic market which is the largest of its kind in the world and is worth around $35 billion. Subsidiaries of Indian pharmaceutical companies which have improved in the rankings include Lupin Pharmaceuticals, Zydus Cadila, Glenmark, Aurobindo and Torrent Pharma.

Industry experts suggest that the growth of Indian companies in this market is due to the selection of their products and because they have been quick in being first to file for the Abbreviated New Drug Application (ANDA). The ANDA gives companies 180 days of exclusivity for selling a generic version of a patented drug. These companies have also been able to satisfy the regulatory norms by supplying quality products to a market which has one of the strictest quality screening checks.

Zydus Cadila was the biggest mover in rankings after gaining 5 places in the rankings to 12th. Lupin Pharmaceuticals, the highest ranked of these companies is now ranked 5th after being 8th last year, whilst Aurobindo is now 13th from 14th and Glenmark is at 18 from 22. Torrent Pharma is the lowest ranked of these companies after increasing 4 places to 26th.

International Government Affairs & Corporate Relations Consultants for Emerging Markets

Enhanced by Zemanta
 

Leave a Comment

« | Home | »